Advances in anti-invasive fungal drug delivery systems.
10.3724/zdxbyxb-2023-0030
- Author:
Zhongyi MA
1
;
Xinyu WANG
2
;
Chong LI
3
Author Information
1. College of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China. mazy448@163.com.
2. College of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China.
3. College of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China. chongli2009@gmail.com.
- Publication Type:Journal Article
- Keywords:
Antifungal infection drugs;
Biomimetic carrier;
Drug delivery system;
Invasive fungal infection;
Review;
Synthetic carrier
- MeSH:
Antifungal Agents/therapeutic use*;
Drug Delivery Systems;
Amphotericin B/therapeutic use*;
Liposomes/chemistry*;
Nanoparticles;
Drug Carriers
- From:
Journal of Zhejiang University. Medical sciences
2023;52(3):318-327
- CountryChina
- Language:English
-
Abstract:
Currently, the first-line drugs for invasive fungal infections (IFI), such as amphotericin B, fluconazole and itraconazole, have drawbacks including poor water solubility, low bioavailability, and severe side effects. Using drug delivery systems is a promising strategy to improve the efficacy and safety of traditional antifungal therapy. Synthetic and biomimetic carriers have greatly facilitated the development of targeted delivery systems for antifungal drugs. Synthetic carrier drug delivery systems, such as liposomes, nanoparticles, polymer micelles, and microspheres, can improve the physicochemical properties of antifungal drugs, prolong their circulation time, enhance targeting capabilities, and reduce toxic side effects. Cell membrane biomimetic drug delivery systems, such as macrophage or red blood cell membrane-coated drug delivery systems, retain the membrane structure of somatic cells and confer various biological functions and specific targeting abilities to the loaded antifungal drugs, exhibiting better biocompatibility and lower toxicity. This article reviews the development of antifungal drug delivery systems and their application in the treatment of IFI, and also discusses the prospects of novel biomimetic carriers in antifungal drug delivery.
